Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
Investors
(02186.HK)
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of:
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
2026
Search
17
2026-11
VOLUNTARY ANNOUNCEMENT COMPLETION OF PHASE 3 TRIAL OF BA1104 (NIVOLUMAB) IN CHINA, WITH PRIMARY ENDPOINT MET
06
2026-11
VOLUNTARY ANNOUNCEMENT CDE APPROVAL OF IND APPLICATION IN CHINA FOR BA2201, A TL1A/IL-23 BISPECIFIC ANTIBODY FOR THE TREATMENT OF IBD (105KB)
05
2026-11
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
30
2026-10
VOLUNTARY ANNOUNCEMENT THE COMPANY ENTERS INTO LICENSING AGREEMENT FOR DENOSUMAB INJECTION 60 MG IN JAPAN
22
2026-10
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN PHASE I CLINICAL TRIAL OF BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN) IN CHINA
09
2026-10
CONTINUING CONNECTED TRANSACTIONS PROMOTION COOPERATION AGREEMENT
07
2026-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
29
2026-09
INTERIM REPORT 2026
17
2026-09
Next Day Disclosure Return
14
2026-09
VOLUNTARY ANNOUNCEMENT CDE APPROVAL OF IND APPLICATION FOR BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN)
1
2
3
4
5